Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
← catalyst calendarNCT06138613 · readout in 406 d
Sponsored by Vanda Pharmaceuticals (industry) · VNDA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
705actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-27 | actual | When the study began enrolling |
| Primary completion | 2027-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Motion Sickness
Intervention
- Drug: Tradipitant
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability of tradipitant as measured by reporting of adverse events (AEs).
measured through study completion, approximately 1 year
Permalink · VNDA's whole pipeline · Catalyst calendar · Every registered study · What changed